Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06280781
NA

Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)

Sponsor: Imperial College London

View on ClinicalTrials.gov

Summary

The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy. Research Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS (fewer PSA tests, biopsies and clinic visits)? Patients will be allocated in a 1.1 ratio to either MRI scans or the current NICE defined standard. Randomisation will be blocked (random block size) and stratified by MRI visibility of lesions (3 categories \[ no visible lesion, diffuse changes, discrete visible lesion\]), cancer Grade Group (GG1, GG2) and time since diagnosis. This study will not be blinded to patients or physicians.

Official title: A Randomised Controlled Trial of Regular MRI Scans Compared to Standard Care in Patients With Prostate Cancer Managed Using Active Surveillance

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1263

Start Date

2024-05-24

Completion Date

2032-06

Last Updated

2026-03-30

Healthy Volunteers

No

Conditions

Interventions

DIAGNOSTIC_TEST

MRI Scans

The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI. Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4.

Locations (12)

Heatherwood Hospital

Ascot, Berkshire, United Kingdom

Darent Valley Hospital

Dartford, Kent, United Kingdom

Bradford Royal Infirmary

Bradford, United Kingdom

St Peter's Hospital

Chertsey, United Kingdom

Charing Cross Hospital

London, United Kingdom

Kings College London

London, United Kingdom

West Middlesex Hospital

London, United Kingdom

Freeman Hospital

Newcastle upon Tyne, United Kingdom

Glan Clywd Hospital

Rhyl, United Kingdom

Northern Lincolnshire and Goole NHS Foundation Trust

Scunthorpe, United Kingdom

Southampton University Hospital

Southampton, United Kingdom

North Cumbria

Whitehaven, United Kingdom